Dogwood Therapeutics Inc DWTX.OQ DWTX.O is expected to show no change in quarterly revenue when it reports results on November 7 for the period ending September 30 2024
LSEG's mean analyst estimate for Dogwood Therapeutics Inc is for a loss of $1.18 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Dogwood Therapeutics Inc is 25.00, above its last closing price of $4.62.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -1.56 | -1.58 | -1.25 | Beat | 21 |
Jan. 1 2024 | -1.00 | -1.75 | -75 | ||
Jan. 1 0001 | -2.24 | -1.50 | 33.3 | ||
Sep. 30 2023 | -2.37 | -2.37 | -1.50 | Beat | 36.8 |
Jan. 1 0001 | -1.75 | -1.75 | -2.00 | Missed | -14.3 |
Mar. 31 2023 | -5.00 | -5.00 | -2.00 | Beat | 60 |
Jan. 1 0001 | -3.87 | -3.87 | -2.75 | Beat | 29 |
Jan. 1 0001 | -11.50 | -12.25 | -7.00 | Beat | 42.9 |
This summary was machine generated November 6 at 14:10 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。